Comparative Pharmacology
Head-to-head clinical analysis: FLURBIPROFEN versus TOLECTIN DS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLURBIPROFEN versus TOLECTIN DS.
FLURBIPROFEN vs TOLECTIN DS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclooxygenase (COX) inhibitor, reducing prostaglandin synthesis; nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic effects.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.
Oral: 50-100 mg every 6-8 hours; maximum 300 mg/day. Ophthalmic: 1 drop every 30 minutes starting 2 hours before surgery, then 1 drop every 4-6 hours for 24-48 hours post-surgery.
400 mg orally three times daily; maximum dose 1800 mg/day.
None Documented
None Documented
Terminal elimination half-life: 3-4 hours (healthy adults) in short-term use; prolonged to 6-12 hours in elderly or renal impairment.
Clinical Note
moderateFlurbiprofen + Gatifloxacin
"Flurbiprofen may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateFlurbiprofen + Rosoxacin
"Flurbiprofen may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateFlurbiprofen + Levofloxacin
"Flurbiprofen may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateFlurbiprofen + Trovafloxacin
Terminal elimination half-life approximately 1 hour; clinical context: requires frequent dosing every 6-8 hours due to short half-life.
Renal: 70% as conjugated metabolites (e.g., glucuronides) and <5% unchanged; biliary/fecal: 30%, with enterohepatic circulation.
Primarily renal, 95% of a dose excreted in urine as glucuronide conjugates and oxidative metabolites; less than 5% fecal.
Category D/X
Category C
NSAID
NSAID
"Flurbiprofen may increase the neuroexcitatory activities of Trovafloxacin."